The post is a summary of how things look today and under related reading I have included some past posts that may offer a few more details on how the shift it taking place today. Things are also happening and humming as well in China and you can search and find some recent relative posts here as...
Posted to
The Medical Quack .... by Barbara Duck
on 11-20-2008
Filed under: Pharma/FDA News, My Commentaries, healthcare, Pharma, clinical trials, R and D, India, Economics, Mayo Clinic, Outsourcing, Employment, China pharma
This is a real interesting merger with a biotech company patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system merging with a company that provides personal health records, both companies from California. Favrille is involved in clinical trials...
Posted to
The Medical Quack .... by Barbara Duck
on 11-10-2008
Filed under: Medically Related, Technology, healthcare, Biotech, PHR, Google Health, Cancer, clinical trials, Personal Health Records, R and D
Great effort on the members of Congress to “ask”, but the end result is what counts. R and D with major pharmaceutical companies is presently in the business of moving overseas to India and China, as well as some clinical trials, so the impact of the request from the members of Congress may or...
Posted to
The Medical Quack .... by Barbara Duck
on 11-04-2008
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, clinical trials, Pfizer, China, R and D, India, Outsourcing
The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
on 11-02-2008
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost...
I am guessing this stands to be topic for all in the Pharma business to keep an eye on. There are those in the Indian government too with reservations. The whole idea here is to save money over what the same might cost in the US, as reported earlier, 1/5 is the cost for R and D, thus this...